Literature DB >> 10460557

Adrenocortical function in critically ill patients 24 h after a single dose of etomidate.

A Absalom1, D Pledger, A Kong.   

Abstract

We compared the effects of single doses of etomidate and thiopentone on adrenocortical function in a randomised controlled clinical trial involving 35 critically ill patients who needed a general anaesthetic. Just before induction of anaesthesia, a baseline blood cortisol sample was taken. Twenty-four hours later we performed a short adrenocorticotrophic hormone stimulation test. No patient had a low cortisol level (< 160 nmol.l-1) at any time during the study. Baseline, pre-ACTH and post-ACTH cortisol levels were similar in the two groups. However, significantly more patients in the etomidate group had an ACTH-stimulated cortisol increment < 200 nmol.l-1. The clinical significance of these findings is not clear, but we conclude that single doses of etomidate may interfere with cortisol synthesis for at least 24 h in the critically ill.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10460557     DOI: 10.1046/j.1365-2044.1999.01003.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  55 in total

Review 1.  Comparative tolerability of sedative agents in head-injured adults.

Authors:  Susan C Urwin; David K Menon
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function.

Authors:  Joseph F Cotten; Stuart A Forman; Joydev K Laha; Gregory D Cuny; S Shaukat Husain; Keith W Miller; Hieu H Nguyen; Elizabeth W Kelly; Deirdre Stewart; Aiping Liu; Douglas E Raines
Journal:  Anesthesiology       Date:  2010-03       Impact factor: 7.892

3.  ICU physicians should abandon the use of etomidate!

Authors:  Djillali Annane
Journal:  Intensive Care Med       Date:  2005-01-27       Impact factor: 17.440

4.  Adrenal axis function does not appear to be associated with hemodynamic improvement in septic shock patients systematically receiving glucocorticoid therapy.

Authors:  Jerome Morel; Christophe Venet; Yannis Donati; David Charier; Jerome Liotier; Delphine Frere-Meunier; Stephane Guyomarc'h; Eric Diconne; Jean Claude Bertrand; Bertrand Souweine; Laurent Papazian; Fabrice Zeni
Journal:  Intensive Care Med       Date:  2006-06-20       Impact factor: 17.440

Review 5.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 6.  Clinical and molecular pharmacology of etomidate.

Authors:  Stuart A Forman
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

Review 7.  The effect of etomidate on adrenal function in critical illness: a systematic review.

Authors:  Stewart G Albert; Srividya Ariyan; Ayesha Rather
Journal:  Intensive Care Med       Date:  2011-03-04       Impact factor: 17.440

8.  Hypoadrenalism following trauma: is sepsis always necessary?

Authors:  Ian M Paquette; Kenneth W Burchard
Journal:  Int J Clin Exp Med       Date:  2008-10-08

9.  Carboetomidate: an analog of etomidate that interacts weakly with 11β-hydroxylase.

Authors:  Sivananthaperumal Shanmugasundararaj; Xiaojuan Zhou; Jens Neunzig; Rita Bernhardt; Joseph F Cotten; Rile Ge; Keith W Miller; Douglas E Raines
Journal:  Anesth Analg       Date:  2013-03-14       Impact factor: 5.108

10.  Etomidate, adrenal function, and mortality in critically ill patients.

Authors:  Jacob E Sunshine; Steven Deem; Noel S Weiss; N David Yanez; Stephen Daniel; Katherine Keech; Marcia Brown; Miriam M Treggiari
Journal:  Respir Care       Date:  2013-04       Impact factor: 2.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.